

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|  |  |  |  |   |
|--|--|--|--|---|
| 1. Name and Address of Reporting Person *<br><b>FROM STEPHEN</b><br>(Last) (First) (Middle)<br><b>C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108</b><br>(Street)<br><b>WALTHAM, MA 02452</b><br>(City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year)<br><b>02/12/2015</b> | 3. Issuer Name and Ticker or Trading Symbol<br><b>EYEGATE PHARMACEUTICALS INC [EYEG]</b>   |  |   |
|  |  | 4. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br><input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner<br><input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)<br><b>President and CEO</b> |  | 5. If Amendment, Date Original Filed (Month/Day/Year) |
|  |  | 6. Individual or Joint/Group Filing (Check Applicable Line)<br><input checked="" type="checkbox"/> Form filed by One Reporting Person<br><input type="checkbox"/> Form filed by More than One Reporting Person   |  |   |

### Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock                    | 41,340  | D  |   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |                            | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-----------------|---|----------------------------|--|---|---|
|  | Date Exercisable   | Expiration Date | Title   | Amount or Number of Shares |  |   |   |
| Stock Option (right to buy)                | (1)  | 07/25/2016      | Common Stock  | 52,990                     | \$ 0.65  | D   |   |
| Stock Option (right to buy)                | (1)  | 01/10/2017      | Common Stock  | 22,803                     | \$ 0.65  | D   |   |
| Stock Option (right to buy)                | (1)  | 04/15/2018      | Common Stock  | 27,803                     | \$ 0.65  | D   |   |
| Stock Option (right to buy)                | (1)  | 01/23/2019      | Common Stock  | 2,157                      | \$ 0.65  | D   |   |
| Stock Option (right to buy)                | (1)  | 01/23/2019      | Common Stock  | 278                        | \$ 0.65  | D   |   |
| Stock Option (right to buy)                | (1)  | 01/29/2020      | Common Stock  | 54,009                     | \$ 0.65  | D   |   |
| Stock Option (right to buy)                | (1)  | 06/25/2020      | Common Stock  | 34,672                     | \$ 0.65  | D   |   |
| Stock Option (right to buy)                | (1)  | 01/14/2021      | Common Stock  | 4,554                      | \$ 0.65  | D   |   |
| Stock Option (right to buy)                | (1)  | 01/14/2021      | Common Stock  | 47,439                     | \$ 0.65  | D   |   |
| Stock Option (right to buy)                | (2)  | 12/23/2022      | Common Stock  | 10,929                     | \$ 0.65  | D   |   |

## Reporting Owners

| Reporting Owner Name / Address | Relationships |           |         |       |
|--------------------------------|---------------|-----------|---------|-------|
|                                | Director      | 10% Owner | Officer | Other |
|                                |               |           |         |       |

|   |   |  |                   |  |
|---|---|--|-------------------|--|
| FROM STEPHEN<br>C/O EYEGATE PHARMACEUTICALS, INC.<br>271 WAVERLEY OAKS ROAD, SUITE 108<br>WALTHAM, MA 02452 | X |  | President and CEO |  |
|---|---|--|-------------------|--|

**Signatures**

|  |  |                     |
|--|--|---------------------|
| /s/ Authorized Signatory*                      |  | 02/12/2015          |
| <small>**Signature of Reporting Person</small> |  | <small>Date</small> |

**Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Immediately exercisable.
- (2) The option became exercisable as to 33% of the shares underlying the option on Dec. 23, 2013 with 2.79% of the shares underlying the option vesting monthly thereafter.

**Remarks:**

\*Signed under power of attorney on behalf of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.